Liver fibrosis and progression to cirrhosis are key predictors of NASH mortality9
-
Risk of all-cause mortality is highest in patients with cirrhosis of the liver9

-
According to a meta-analysis analyzing fibrosis stage-specific mortality ratios of 5 NAFLD cohort studies, risk of liver-related mortality increases substantially in patients with liver fibrosis, with significantly higher rates observed in patients with stage 2 fibrosis or higher9
-
NASH is the fastest-growing cause of hepatocellular carcinoma (HCC) in the US,12 with a 940% increase of NASH-related HCC as an indication for liver transplant between 2004 and 201613
–However, cardiovascular disease is the leading cause of death in patients with NAFLD4
-
Complications of NASH may also negatively impact health-related quality of life,* particularly for patients
with cirrhosis10,11
*Assessed using the Short Form 36 questionnaire and the Chronic Liver Disease Questionnaire, 2 validated health-related quality of life questionnaires used frequently in the NASH literature.10